Hemant Sarin

Summary

Publications

  1. pmc Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ther Deliv 1:289-305. 2010
  2. pmc Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Angiogenes Res 2:14. 2010
  3. ncbi request reprint On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA
    Recent Pat CNS Drug Discov 5:239-52. 2010
  4. pmc Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 6:80. 2008
  5. pmc Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 7:77. 2009
  6. pmc Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 7:33. 2009

Detail Information

Publications6

  1. pmc Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ther Deliv 1:289-305. 2010
    ..In this article, the physiologic and ultrastructural basis of this novel translational approach for the treatment of CNS, as well as non-CNS, solid cancers is reviewed...
  2. pmc Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Angiogenes Res 2:14. 2010
    ....
  3. ncbi request reprint On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA
    Recent Pat CNS Drug Discov 5:239-52. 2010
    ....
  4. pmc Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 6:80. 2008
    ..Using functionalized polyamidoamine dendrimer generations 1 through 8, we investigated how nanoparticle size influences particle accumulation within malignant glioma cells...
  5. pmc Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 7:77. 2009
    ..Herein I discuss this novel strategy to improve the effectiveness of systemic chemotherapy for the treatment of malignant brain tumors and the therapeutic implications thereof...
  6. pmc Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 7:33. 2009
    ....